Physician profile
Parvez Mir
NPI 1992743231
$3,038.49
in general payments reported to CMS, 2019-2025
26 companies · $560 in 2025
The $560 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $159 · 2021: $210 · 2022: $440 · 2023: $802 · 2024: $507 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,869.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $539.25 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $500.50 | 2023-2025 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.21 | 2022-2025 | Ofev |
| Abbvie INC. | $234.98 | 2021-2024 | |
| Inari Medical, INC. | $225.51 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Olympus America INC. | $144.45 | 2024 | Spin Vision Video Processor |
| Horizon Therapeutics Plc | $125.00 | 2023 | Tepezza |
| Merck Sharp & Dohme LLC | $118.13 | 2022-2025 | Capvaxive |
| Insmed, INC. | $114.10 | 2019-2025 | Arikayce |
| Melinta Therapeutics, LLC | $102.82 | 2019-2023 | Rezzayo, Kimyrsa, Orbactiv |
| Allergan, INC. | $95.01 | 2019-2020 | |
| American Regent | $75.99 | 2025 | Injectafer |
| Shire North American Group INC | $73.74 | 2019 | |
| Gilead Sciences, INC. | $50.84 | 2021-2023 | |
| Shionogi INC | $49.22 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $43.26 | 2019-2020 | |
| Baxter Healthcare | $42.32 | 2022 | |
| Ani Pharmaceuticals, INC. | $32.07 | 2025 | Purified Cortrophin Gel |
| Dynavax Technologies Corporation | $29.77 | 2023 | Heplisav-B |
| Pfizer INC. | $29.57 | 2025 | |
| Exact Sciences Corporation | $28.66 | 2024 | Cologuard Collection Kit |
| Viiv Healthcare Company | $21.33 | 2023 | Rukobia |
| Amgen INC. | $20.32 | 2023 | Tezspire |
| Emd Serono, INC. | $17.19 | 2023 | Serostim |
| Otsuka America Pharmaceutical, INC. | $16.25 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parvez Mir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.